Genome editing specialist Emendo Biotherapeutics has agreed a licensing deal with Takeda Pharmaceutical (TYO: 4502).
Under the terms of the deal, the Japanese pharma giant has secured an option to use OMNI, Emendo’s nuclease program, to edit two genes as part of its research and development efforts.
OMNI is designed to enable very specific gene editing which minimizes off target cuts and allows for highly focused therapeutic intervention in complex genetic diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze